Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1995 7
1996 8
1997 15
1998 11
1999 25
2000 41
2001 46
2002 69
2003 95
2004 122
2005 160
2006 157
2007 150
2008 138
2009 136
2010 129
2011 142
2012 130
2013 143
2014 105
2015 78
2016 80
2017 70
2018 70
2019 65
2020 66
2021 54
2022 51
2023 40
2024 55
2025 54
2026 41

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,301 results

Results by year

Filters applied: . Clear all
Page 1
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.
Klein LR, Driver BE, Miner JR, Martel ML, Hessel M, Collins JD, Horton GB, Fagerstrom E, Satpathy R, Cole JB. Klein LR, et al. Ann Emerg Med. 2018 Oct;72(4):374-385. doi: 10.1016/j.annemergmed.2018.04.027. Epub 2018 Jun 7. Ann Emerg Med. 2018. PMID: 29885904
The purpose of this study is to compare haloperidol, olanzapine, midazolam, and ziprasidone to treat agitation. METHODS: This was a prospective observational study of consecutive patients receiving intramuscular medication to treat agitation in the ED. ...CONCLUSION: Intra …
The purpose of this study is to compare haloperidol, olanzapine, midazolam, and ziprasidone to treat agitation. METHODS: This was a p …
Pediatric ziprasidone ingestions.
Rowden AK, Fasano CJ, O'Malley GF. Rowden AK, et al. J Med Toxicol. 2010 Dec;6(4):467. doi: 10.1007/s13181-010-0104-8. J Med Toxicol. 2010. PMID: 20680540 Free PMC article. No abstract available.
Ziprasidone: a new atypical antipsychotic.
Keck PE Jr, McElroy SL, Arnold LM. Keck PE Jr, et al. Expert Opin Pharmacother. 2001 Jun;2(6):1033-42. doi: 10.1517/14656566.2.6.1033. Expert Opin Pharmacother. 2001. PMID: 11585006 Review.
This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a MEDLINE search (completed for citations to early 2001). ...Like other …
This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citat …
Drug safety evaluation of ziprasidone.
Citrome L. Citrome L. Expert Opin Drug Saf. 2011 May;10(3):437-48. doi: 10.1517/14740338.2011.560114. Epub 2011 Feb 19. Expert Opin Drug Saf. 2011. PMID: 21332416 Review.
INTRODUCTION: Ziprasidone is a second-generation antipsychotic approved for the treatment of schizophrenia and bipolar disorder. ...Ziprasidone's principal advantage over some other second-generation antipsychotics has been its overall favorable weight and me …
INTRODUCTION: Ziprasidone is a second-generation antipsychotic approved for the treatment of schizophrenia and bipolar disorder. ... …
Efficacy of Different Combination Therapies for Mania in Bipolar Disorder: A Systematic Review and Meta-Analysis.
Yao P, Ni P, Yin L. Yao P, et al. Brain Behav. 2025 Dec;15(12):e71139. doi: 10.1002/brb3.71139. Brain Behav. 2025. PMID: 41431288 Free PMC article.
Furthermore, ziprasidone was associated with significantly greater increases in BDNF and T(3) levels after treatment. CONCLUSION: Although the efficacy of ziprasidone plus mood stabilizers is comparable to that of olanzapine plus mood stabilizers in the treatment of …
Furthermore, ziprasidone was associated with significantly greater increases in BDNF and T(3) levels after treatment. CONCLUSION: Alt …
Ziprasidone, a new atypical antipsychotic drug.
Carnahan RM, Lund BC, Perry PJ. Carnahan RM, et al. Pharmacotherapy. 2001 Jun;21(6):717-30. doi: 10.1592/phco.21.7.717.34575. Pharmacotherapy. 2001. PMID: 11401184 Review.
Like the existing atypical agents, ziprasidone has a rate of extrapyramidal side effects similar to that of placebo and does not cause significant elevations in prolactin levels. In contrast, ziprasidone has a low propensity for causing weight gain. For patients req …
Like the existing atypical agents, ziprasidone has a rate of extrapyramidal side effects similar to that of placebo and does not caus …
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
Citrome L, Yang R, Glue P, Karayal ON. Citrome L, et al. Schizophr Res. 2009 Jun;111(1-3):39-45. doi: 10.1016/j.schres.2009.03.009. Epub 2009 Apr 17. Schizophr Res. 2009. PMID: 19375893 Clinical Trial.
BACKGROUND: Higher dose ziprasidone has been associated with improved treatment outcomes in patients with schizophrenia or schizoaffective disorder. ...METHOD: Data were analyzed for the first 28 days from 4 pivotal, randomized, double-blind, fixed-dose ziprasidone …
BACKGROUND: Higher dose ziprasidone has been associated with improved treatment outcomes in patients with schizophrenia or schizoaffe …
Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.
Preskorn SH. Preskorn SH. Clin Pharmacokinet. 2005;44(11):1117-33. doi: 10.2165/00003088-200544110-00002. Clin Pharmacokinet. 2005. PMID: 16231965 Review.
The intramuscular formulation of ziprasidone, ziprasidone mesylate, uses sulfobutylether beta-cyclodextrin to solubilise the drug by complexation. ...No clinically significant age-, sex- or race-related effects on the pharmacokinetics of intramuscular or oral zip …
The intramuscular formulation of ziprasidone, ziprasidone mesylate, uses sulfobutylether beta-cyclodextrin to solubilise the d …
Physiologically-based pharmacokinetics of ziprasidone in pregnant women.
Biesdorf C, Martins FS, Sy SKB, Diniz A. Biesdorf C, et al. Br J Clin Pharmacol. 2019 May;85(5):914-923. doi: 10.1111/bcp.13872. Epub 2019 Mar 11. Br J Clin Pharmacol. 2019. PMID: 30669177 Free PMC article.
The aim of this study was to predict the PK of ziprasidone in pregnant women. METHODS: A full physiologically-based pharmacokinetic (PBPK) model of ziprasidone was developed and validated for the non-pregnant population (healthy adults, paediatrics, geriatrics), and …
The aim of this study was to predict the PK of ziprasidone in pregnant women. METHODS: A full physiologically-based pharmacokinetic ( …
Ziprasidone augmentation for anxious depression.
Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI. Ionescu DF, et al. Int Clin Psychopharmacol. 2016 Nov;31(6):341-6. doi: 10.1097/YIC.0000000000000133. Int Clin Psychopharmacol. 2016. PMID: 27306192 Free PMC article. Clinical Trial.
Hamilton Depression Rating Scales total change scores from baseline and endpoint were not significantly different (interaction term P=0.91) in patients with anxious depression on ziprasidone augmentation (n=19; -9.1 4.9) or placebo (n=19; -6.1 8.9) versus patients without …
Hamilton Depression Rating Scales total change scores from baseline and endpoint were not significantly different (interaction term P=0.91) …
2,301 results